



BIOGNOSYS

YOUR PARTNER IN PROTEOMICS FOR LIFE SCIENCE RESEARCH & DEVELOPMENT

Biognosys leads the way in revolutionizing the field of proteomics with its proprietary mass spectrometry technologies. Offering the most advanced solutions for both in-house and outsourced research, we empower life science organizations to gain unparalleled biological insights.

Founded in 2008 as a spin-off from Prof. Ruedi Aebersold's proteomics lab at ETH Zurich, Biognosys has emerged as a prominent leader in next-generation proteomics. Anchored by our Zurich headquarters and lab facility, we are continuously expanding our operations, most recently establishing offices and a lab facility in Massachusetts, US. Our global presence empowers us to serve our vast customer base across biotechnology, pharmaceuticals, and academia.

In early 2023, Biognosys forged a strategic partnership with Bruker, joining forces to advance proteomics and widen access to cutting-edge technologies across the life science community. Together we push the boundaries of proteomics and empower researchers in industry and academia with unparalleled tools and insights.


™BIOGNOSYS &





GLOBAL PRESENCE

We have offices and lab-facilities in Zurich (Switzerland) and Massachusetts (US), as well as multiple representatives across Europe and the US, catering to our network of more than 800 partners around the world.





> 50 %

PhD scientists on staff



compliant facility



10/20

top pharma companies as clients/partners

OUR SERVICES

CLINICAL

UNIQUE SUITE OF PROTEOMICS RESEARCH PLATFORMS FOR EVERY APPLICATION



Structural proteomics at peptide-level for drug target identification and validation The Biognosys **TrueTarget**® proteomics platform uniquely addresses the most pressing challenges in early drug discovery by identifying on- and off-targets to accelerate and de-risk drug development throughout the pipeline. It is powered by Limited Proteolysis Mass Spectrometry (LiP-MS), a proprietary, patented chemoproteomics technology codeveloped by Biognosys. TrueTarget® is the

only tool to probe structural changes across the complete proteome with peptide-level resolution, providing unique insights into compound binding and target identification.

Applications

DRUG TARGET DECONVOLUTION
DRUG TARGET VALIDATION

Deepest unbiased proteome exploration, covering over 13,000 proteins

The Biognosys **TrueDiscovery**® platform offers integrated proteomics solutions across the entire drug development pipeline. It is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, a quantification technology co-invented and patented by Biognosys. TrueDiscovery® is the only platform that searches the complete proteome of tissue and biofluids samples to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms with unbeatable specificity on a large scale. The generated data are highly reproducible

and easily transferrable to clinical assays. Studies can be performed in a GLP certified and GCP compliant environment.

Applications

TISSUE BIOMARKER DISCOVERY
PHOSPHO PROTEOME PROFILING
IMMUNO PEPTIDOME PROFILING
DISEASE PATHWAY STUDIES
MECHANISM OF ACTION STUDIES
POPULATION HEALTH SCREENING



High-precision customizable clinical and pharmacodynamic biomarker panels

The Biognosys **TrueSignature**® platform provides high-precision customizable proteomics panels for pharmacodynamic readouts and clinical biomarker monitoring. Parallel Reaction Monitoring (PRM) and SureQuant mass spectrometry power the platform, allowing complete customization and independence from affinity-based recognition and reagent availability. The TrueSignature® panels offer versatile protein combination options, including single proteins,

multiplex panels, and hyperplex panels of up to 800 proteins. TrueSignature panels can be developed within weeks and are available both as a standalone solution or an integrated solution, in which insights from TrueDiscovery studies guide the choice of proteins in the custom panel.

Applications

PHARMACO DYNAMIC BIOMARKERS
CLINICAL BIOMARKER PANELS

OUR PRODUCTS

HIGH PERFORMANCE KITS AND SOFTWARE SOLUTIONS

Our complete suite of proteomics solutions empowers researchers to perform cutting-edge proteomics in-house. With software solutions for a wide range of proteomics analysis, reference peptide kits for both discovery and targeted approaches, as well as sample preparation kits and quality control tools, proteomics research has never been easier.



PQ500™ Reference Peptide Kit

PQ500 offers accurate identification and quantification of 500+ human plasma and serum proteins. The kit allows for biomarker detection across over six

orders of magnitude, providing results that are comparable across platforms and laboratories. PQ500 is fully compatible with MRM, PRM, SureQuant, DIA, as well as native and depleted plasma.



The gold standard for DIA proteomics analysis

Our flagship software, Spectronaut®, offers the best performing library-free DIA analysis on the market. With its novel directDIA+™ workflow, AI augmentation, and versatile Pulsar library generation, DIA is more powerful than ever.

Data-Independent Acquisition (DIA)



Targeted proteomics analysis simplified

SpectroDive™ is an unmatched solution for high-throughput targeted proteomics. With machine learning-assisted peak picking, high-precision iRT calibration-assisted and automated FDR control, SpectroDive is the perfect partner for your targeted proteomics analysis

Targeted Proteomics (MRM, PRM, Surequant)



Raising standards for DDA data analysis

SpectroMine™ provides users with the fastest and most accurate identification available. Our software for DDA analysis is equipped with deep learning augmented search algorithms, isobaric labelling quantification, and LFQ DDA optimized workflows.

Data-Dependent Acquisition (DDA)



The free software for Proteomics Facility Monitoring

Quality control is easy with our iRT Kitbased software QuiC™. QuiC allows you to monitor the performance of all instruments in your proteomics facility and set individual thresholds for all instrument parameters practically in real-time.

Quality Control

BIOGNOSYS: A LEADING INNOVATOR IN PROTFOMICS

As the leading inventor and innovator of mass spectrometry-based proteomics solutions, we offer industry-leading technology and actionable insights that you can trust to accelerate your research.



> 15

vears of innovation in Proteomics



> 50% PhD scientists

on staff



granted

international patents



publications on Biognosys' technology



> 15.000

saft lab and LC-MS facilities



alobal customers

YOUR PARTNER THROUGHOUT THE RESEARCH JOURNEY

Biognosys is your trusted partner whether you perform your proteomics in-house or require end-to-end service solutions. We are committed to providing the assistance you need throughout the discovery and development journey with attentive pre-study consultation, high-quality and timely data delivery, insightful reporting, and easy-to-use software solutions and kits.

Get in touch via biognosys.com/contact to discuss your needs with one of our scientific or technical consultants.

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. We make the proteome actionable to empower research, drug development, and clinical decision-making with our versatile portfolio of mass spectrometry-based proteomics research services, software and kits. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types.

